Mesenchymal stem cells in the treatment of diabetes mellitus: perspectives

Перспективы применения мезенхимальных стволовых клеток в лечении сахарного диабета
Olga Ulyanova 1, Temirlan Karibekov 2, Galiya Shaimardanova 2, Larissa Kozina 3
More Detail
1 Endocrine Disturbances Department, National Scientific Medical Center, Astana, Republic of Kazakhstan
2 Scientific Research Management Department, National Scientific Medical Center, Astana, Republic of Kazakhstan
3 Clinical and Diagnostic Laboratory, National Scientific Medical Center, Astana, Republic of Kazakhstan
J CLIN MED KAZ, Volume 3, Issue 49, pp. 32-34. https://doi.org/10.23950/1812-2892-JCMK-00591
OPEN ACCESS 3145 Views 2347 Downloads
Download Full Text (PDF)

ABSTRACT

Over recent decades, diabetes mellitus remains one of the main public healthcare problems worldwide with a tendency to steady growth. Actual prevalence of only type 2 diabetes mellitus among adults (20-79 years old) in Kazakhstan was higher than it was expected and amounted to 8.2% according to the Kazakh epidemiological study NOMAD. Diabetes mellitus is a major risk factor for ischemic heart disease and stroke, which collectively account for high rates of morbidity and mortality among adult patients. Transplantation of mesenchymal stem cells was considered to be the most promising treatment approach for diabetes mellitus.
Keywords: c-peptide, adipokines, pancreatic islet cell regeneration

CITATION

Ulyanova O, Karibekov T, Shaimardanova G, Kozina L. Mesenchymal stem cells in the treatment of diabetes mellitus: perspectives. Journal of Clinical Medicine of Kazakhstan. 2018;3(49):32-4. https://doi.org/10.23950/1812-2892-JCMK-00591

REFERENCES

  • Dedov II, Balabolkin MI, Klebanova EM, Kreminskaya VM, Tchazova T.E. Diabetes mellitus: pathogenesis, classification, diagnostic and treatment [in Russian]. Medicine; 2003. p.171.
  • Atlas IDF-7th edition, 2015. Available from: www.diabetesatlas.org
  • Tokhtarova N, Bazarbekova R, Dosanova A. Prevalence of type 2 diabetes mellitus among adult population of Kazakhstan [in Russian]. Medicine. 2017;6(180):43-51. 
  • Robertson RP. Islet transplantation as a treatment for diabetes—a work in progress. A new therapeutic concept. N Engl J Med.2004;7(350):694-705.
  • Bretzel RG, Jahr H, Eckhard M. et al. Islet cell transplantation today. Langenbecks Arch Surg.2007:392(3):239-253.
  • Sheremetyeva ME, Bukharova T., Goldshtein DV. Insulinproduced cells in treatment of insulindependent diabetes mellitus [in Russian]. Genes and cells.2016;1 :24-34.
  • Tuganbekova S, Ulyanova O, Taubaldieva Z, Saparbayev S, Popova N, Kozina L. Fetal pancreatic stem-cell transplant in patients with diabetes mellitus. Exp Clin Transplant. 2015;13(Suppl 3):160-162.
  • Ulyanova O, Taubaldieva Z, Tuganbekova S, et al. Leptin level in patients with type 2 diabetes mellitus after fetal pancreatic stem cell transplant. Exp Clin Transplant. 2016;14(Suppl 3):45-47.
  • Nikonova T, Pekarskaya E, Filippov Yu. Perspectives of applications of stem-cells technologies in treatment of diabetes mellitus [in Russian]. Vrach. 2010; 12:10-13.
  • Borisov MA, Petrakova OS, Gvazava IG. et al. Stem Cells in the Treatment of insulin-dependent diabetes mellitus. Acta Naturae. 2016; 8.(30):31-43.
  • Dedov II, Lisukov IA, Laptev DN. The modern possibilities of stem cells using in diabetes mellitus [in Russian]. Diabetes mellitus. 2014;(2):20–28.
  • Zakiryanov AR, Onischenko NA, Klimenko ED, Pozdnyakov OM. Regeneration stem-cells therapy of diabetes mellitus type 1 and it complications [in Russian].Vestnik RAMS. 2008;3:42-51.
  • Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type I diabetes. Diabetes.2008; 57:1759-1767.
  • Alvarez-Dolado M. Cell fusion: biological perspectives and potential for regenerative medicine. Front Biosci.2007; 12:P.1-12.
  • You S, Thieblemont N, Alyanakian M, Bach JF, Chatenoud L. Transforming growth factor-beta and T-cell-mediated immunoregulation in the control of autoimmune diabetes. Immunol Rev. 2006; 212:185-202.
  • Kehrl JH. Transforming growth factor-beta: an important mediator of immunoregulation. Int J Cell Cloning. 1991;9(5):438-450.
  • Daneshmandi S, Karimi MH, Pourfathollah AA. TGF-β1 transduced mesenchymal stem cells have profound modulatory effects on DCs and T cells. Iran J Immunol. 2017;14(1):13-23.
  • Kurabekova R, Shevchenko O, Tsiroulnikova O. Transforming growth factor β1 at liver transplantation [in Russian]. Russ J Transpl Artif Org.2015;3:76-82.
  • Zulewski H. Stem cells with potential to generate insulin-producing cells in man. SWISS MED WKLY. 2006;136:647-654.
  • Shiraki N, Ogaki S, Kume S. Profiling of embryonic stem cell differentiation. Rev Diabet Stud. 2014;11(1):102-114.
  • Jing Shen, Yu Cheng, Qingwang Han, Yiming Mun et al . Generating insulin-producing cells for diabetic therapy: Existing strategies and new development. Ageing Research Reviews. 2013;12(2):469-478.
  • Marius Strioga, Sowmya Viswanathan, Adas Darinskas et al. Same or Not the Same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells and Development. 2012:4;2724-2752.
  • Fisher S, Hanefeld M, Haffner SM, et al. Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass. Acta Diabetol. 2002;39(3):105-110.
  • Haojie Hao, Jiejie Liu, Jing Shen et al. Multiple intravenous infusions of bone marrow mesenchymal stem cells reverse hyperglycemia in experimental type 2 diabetes rats. Biochemical and Biophysical Research Communications. 2013;436(3):418- 423
  • Shobhit B, Pinaki D, Vinod K et al. Efficacy of autologous bone marrow-derived mesenchymal stem cell and mononuclear cell transplantation in type 2 diabetes mellitus: a randomized, placebo-controlled comparative study. Stem Cells and Development. April 2017; 26(7): 471-481.
  • Zang L., Hao H., Liu J et al. Mesenchymal stem cell therapy in type 2 diabetes mellitus. Diabetol Metab Syndr. 2017;2: 9-36.
  • Cummings BP, Bettaieb A, Graham JL, et al. Subcutaneous administration of leptin normalizes fasting plasma glucose in obese type 2 diabetic UCD-T2DM rats. Proc Natl Acad Sci U S A. 2011;108(35):14670-14675.
  • Denroche HС, Huynh FK, Kieffer TJ. The role of leptin in glucose homeostasis. J Diabetes Investig. 2012;3(2):115-129.
  • Meek TH, Morton GJ. The role of leptin in diabetes: metabolic effects. Diabetologia. 2016;59(5):928-932.